Chronic Lymphocytic Leukemia (CLL)*2020

Upfront therapy 
​CLL trialist collaborative group
Immediate versus Delayed therapy and chlorambucil

FCR for untreated CLL
Early results initial paper
CLL8 Trial FCR for untreated CLL
CLL7 Trial FCR vs watch and wait

BTK inhibitors Bcl2 inhibitors and beyond
RESONATE 2 trial Ibrutinib vs chlorambucil in untreated CLL
Ibrutinib plus Venetoclax in untreated CLL, MDACC
Ibrutinib-rituximab vs Chemoimmunotherapy E1912
Ibrutinib-rituxan vs BR
​Ibrutinib-Obinutuzumab vs CLB-Obi, the iLLUMINATE trial
Acalabrutinib+/-Obinutuzumab vs CLB-Obi ELEVATE-TN trial

Relapsed   disease
​Venetoclax-Rituxan ​in R/R CLL the MURANO Trial

​Biology and Prognosis *2020
Binet staging
IgVH mutation is associated with a more aggressive form of CLL
Genomic aberrations and survival in CLL
IGVH

Diffuse large B cell Lymphoma (DLBCL)

Upfront therapy

CHOP vs RCHOP and more in untreated DLBCL
GELA original paper in pts older than 60 LNH-98.5 trial
Long term results of the LNH-98.5 trial
R-EPOCH vs R-CHOP Alliance trial/CALGB 50303 
R-CHOP x4 vs x6 cycles in favorable disease FLYER trial
R-CHOP Ibrutininb vs R-CHOP in non-GCB PHOENIX trial
R-DA-EPOCH in PMBL face 2 trial
R-CHOP vs R-DA-EPOCH in PMBL

Relapsed   disease

Biology and Prognosis
R-IPI is better than IPI in RCHOP treated patients

Myeloma (MM) and Amyloidosis (AL)

Initial therapy

RVD initial therapy phase 2 trial
RVD with transplantation initial therapy IMF 2009 trial
Auto-transplant and maintenance lenalidomide CTN0702 trial
Auto transplant consolidation for myeloma phase 3 Trial IFM

Chronic Myeloid Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL)

Classification
2016 WHO classification of leukemia
Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL

Acute Myeloid Leukemia (AML)

Initial therapy

 Hodgking Lymphoma*1832  (HL)
(click on the link above to see the original  paper by Thomas Hodgkin)

Initial therapy

ABVD + subtotal nodal vs involved field radiation early HL
Chemotherapy+ involved field radiation for early HL H8 trial ​
Chemotherapy STLI in early HL Intergroup trial
Reduce treatment intensity in early HL HD10 Trial  
Omission of XRT in Early HL
NOTES:
* ​The link associated with the disease name, subheading or abbreviation is usually a recent review on the topic or a unique paper about it.  An "*" indicates such paper on the topic is available and the year of paper publication is noted.
The trials are mostly in chronological order
Whenever possible the link directs to the full text version of the paper
This page is in construction, it will be always incomplete and permanently in review. It may not contain all relevant papers. If you think a paper needs to be added please let me know.